Recurrent focal segmental glomerulosclerosis and abatacept: Case report

Experimental and Clinical Transplantation

Volumn 14, Issue 4, 2016, Pages 456-459

  Alkandari, Omar ^a,b   Nampoory, Narayanan ^a,b   Nair, Prasad ^b   Atta, Ahmed ^b   Zakaria, Zakaria ^b   Mosaad, Ahmed ^b   Yagan, Jude ^b   Al Otaibi, Torki ^b  

^a MUBARAK AL KABEER HOSPITAL   (Kuwait)

^b Hamid Al Essa Organ Transplant Center   (Kuwait)

Author keywords

End stage renal disease; Immunosuppression; Pediatric; Renal transplant

Indexed keywords

ADULT; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; DOPPLER DEVICE; HUMAN; IMPLANT; KIDNEY BLOOD FLOW; KIDNEY GRAFT; KIDNEY PERFUSION; LIVING DONOR; MALE; MIDDLE AGED; NEPHRECTOMY; ADVERSE EFFECTS; CHILD; COMPLICATION; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RECURRENT DISEASE; TREATMENT FAILURE;

ABATACEPT; IMMUNOSUPPRESSIVE AGENT;

ABATACEPT; CHILD; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RECURRENCE; TREATMENT FAILURE;

EID: 84982950708     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2014.0154     Document Type: Article

References (14)

1. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978;13(2):159-165.
2. Fernandez-Fresnedo G, Segarra A, González E, et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2009;4(8):1317-1323.
3. Newstead CG. Recurrent disease in renal transplants. Nephrol Dial Transplant. 2003;18(suppl 6):vi68-vi74.
4. Jungraithmayr TC, Hofer K, Cochat P, et al. Screening for NPHS2 mutations may help predict FSGS recurrence after trans plantation. J Am Soc Nephrol. 2011;22(3):579-585.
5. Sethna C, Benchimol C, Hotchkiss H, et al. Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab. J Transplant. 2011;2011: 389542.
6. Canaud G, Martinez F, Noël LH, Mamzer MF, Niaudet P, Legendre C. Therapeutic approach to focal and segmental glo merulosclerosis recurrence in kidney transplant recipients. Transplant Rev (Orlando). 2010;24(3):121-128.
7. Shishido S, Satou H, Muramatsu M, et al. Combination of pulse methylprednisolone infusions with cyclosporine-based immunosuppression is safe and effective to treat recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation. Clin Transplant. 2013;27(2):E143-E150.
8. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-1108.
9. Hoi AY, Littlejohn GO. Abatacept in the treatment of lupus. Expert Opin Biol Ther. 2012;12(10):1399-1406.
10. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-1123.
11. Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013;369(25):2416-2423.
12. Benigni A, Gagliardini E, Remuzzi G. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2014;370(13):1261-1263.
13. Alachkar N, Carter-Monroe N, Reiser J. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2014;370(13):1263-1264.
14. Greka A, Weins A, Mundel P. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2014;370(13):1263-1266.